Predictive cancer genomics--what do we need?
Brenton
James D
JD
Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, CB2 2XZ, Cambridge, UK. jdb1003@cam.ac.uk <jdb1003@cam.ac.uk>
Caldas
Carlos
C
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D000077143:Docetaxel; D004354:Drug Screening Assays, Antitumor; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D023281:Genomics; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017422:Sequence Analysis, DNA; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel